{
  "resourceType": "Bundle",
  "id": "H2Q-MC-LZZT-Bundle-2",
  "type": "message",
  "entry": [
    {
      "resource": {
        "resourceType": "ResearchStudy",
        "id": "H2Q-MC-LZZT-ResearchStudy",
        "text": {
          "status": "generated",
          "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p><b>Generated Narrative</b></p><p><b>identifier</b>: id: H2Q-MC-LZZT (USUAL), id: NCTA12313212 (OFFICIAL), PLAC: NCTA12313212 (SECONDARY)</p><p><b>title</b>: Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimer’s Disease</p><p><b>protocol</b>: <a href=\"PlanDefinition-LZZT-Study-Definition.html\">Generated Summary: url: http://example.org/br-and-r/soa/PlanDefinition/LZZT-Study-Definition; version: 0.1.0; status: active; date: Apr 21, 2021, 3:52:00 PM</a></p><p><b>status</b>: completed</p><p><b>primaryPurposeType</b>: <span title=\"Codes: \">treatment</span></p><p><b>phase</b>: <span title=\"Codes: \">phase-3</span></p><p><b>category</b>: <span title=\"Codes: {http://ncimeta.nci.nih.gov C98388}\">Interventional Study</span>, <span title=\"Codes: {http://ncimeta.nci.nih.gov C15417}\">Randomized Clinical Trial</span>, <span title=\"Codes: {http://ncimeta.nci.nih.gov C15228}\">Double Blind Study</span>, <span title=\"Codes: {http://ncimeta.nci.nih.gov C49648}\">Placebo Control</span>, <span title=\"Codes: {http://ncimeta.nci.nih.gov C82639}\">Parallel Study</span></p><p><b>focus</b>: <span title=\"Codes: {http://ncimeta.nci.nih.gov C152926}\">Xanomeline</span>, <span title=\"Codes: {http://ncimeta.nci.nih.gov C149996}\">Transdermal Patch Dosage Form</span></p><p><b>condition</b>: <span title=\"Codes: {http://snomed.info/sct 26929004}\">Alzheimer's Disease (Disorder)</span>, <span title=\"Codes: {http://snomed.info/sct G30}\">Alzheimer's disease</span>, <span title=\"Codes: {http://snomed.info/sct 10001896}\">Alzheimer's disease</span></p><p><b>contact</b>: Bob James, Ph.D.: ph: 555-555-5555(WORK)</p><h3>RelatedArtifacts</h3><table class=\"grid\"><tr><td>-</td></tr><tr><td>*</td></tr></table><p><b>keyword</b>: <span title=\"Codes: {https://id.nlm.nih.gov/mesh D018721}\">Selective M1 muscarinic agonists</span></p><p><b>description</b>: # Xanomeline (LY246708)\n# Protocol H2Q-MC-LZZT(c) \nSafety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimer’s Disease</p><p><b>sponsor</b>: <a href=\"Organization-EliLillyAndCompany.html\">Generated Summary: id: Eli Lilly and Company (OFFICIAL); <span title=\"Codes: \">crs</span></a></p><p><b>principalInvestigator</b>: <a href=\"Practitioner-SamGetWell.html\">Generated Summary: UPIN: ABC123 (OFFICIAL); active; Samuel Home ; Phone: 555-123-5467; gender: male</a></p><blockquote><p><b>arm</b></p><p><b>name</b>: Placebo</p><p><b>type</b>: <span title=\"Codes: {http://ncimeta.nci.nih.gov C49648}\">C49648</span></p><p><b>description</b>: Placebo arm</p></blockquote><blockquote><p><b>arm</b></p><p><b>name</b>: Low-dose xanomeline arm</p><p><b>type</b>: <span title=\"Codes: {http://ncimeta.nci.nih.gov C174266}\">C174266</span></p><p><b>description</b>: Low-dose xanomeline arm (50 cm2 TTS Formulation E, 54 mg xanomeline)</p></blockquote><blockquote><p><b>arm</b></p><p><b>name</b>: High-dose xanomeline arm</p><p><b>type</b>: <span title=\"Codes: {http://ncimeta.nci.nih.gov C174266}\">C174266</span></p><p><b>description</b>: High-dose xanomeline arm (75 cm2 TTS Formulation E, 81 mg xanomeline)</p></blockquote><blockquote><p><b>objective</b></p><p><b>name</b>: To determine if there is a statistically significant relationship (overall Type 1 error rate, α=.05) between the change in both ADAS-Cog and CIBIC+ scores, and drug dose (0, 50 cm2 [54 mg], and 75 cm2 [81 mg]).</p><p><b>type</b>: <span title=\"Codes: \">primary</span></p></blockquote><blockquote><p><b>objective</b></p><p><b>name</b>: To document the safety profile of the xanomeline TTS.</p><p><b>type</b>: <span title=\"Codes: \">primary</span></p></blockquote><blockquote><p><b>objective</b></p><p><b>name</b>: To assess the dose-dependent improvement in behavior. Improved scores on the Revised Neuropsychiatric Inventory (NPI-X) will indicate improvement in these areas.</p><p><b>type</b>: <span title=\"Codes: \">secondary</span></p></blockquote><blockquote><p><b>objective</b></p><p><b>name</b>: To assess the dose-dependent improvements in activities of daily living. Improved scores on the Disability Assessment for Dementia (DAD) will indicate improvement in these areas.</p><p><b>type</b>: <span title=\"Codes: \">secondary</span></p></blockquote><blockquote><p><b>objective</b></p><p><b>name</b>: To assess the dose-dependent improvements in an extended assessment of cognition that integrates attention/concentration tasks. The Alzheimer’s Disease Assessment Scale-14 item Cognitive Subscale, hereafter referred to as ADAS-Cog (14), will be used for this assessment.</p><p><b>type</b>: <span title=\"Codes: \">secondary</span></p></blockquote><blockquote><p><b>objective</b></p><p><b>name</b>: To assess the treatment response as a function of Apo E genotype.</p><p><b>type</b>: <span title=\"Codes: \">secondary</span></p></blockquote></div>"
        },
        "identifier": [
          {
            "use": "usual",
            "value": "H2Q-MC-LZZT"
          },
          {
            "use": "official",
            "system": "https://clinicaltrials.gov/show/",
            "value": "NCTA12313212"
          },
          {
            "use": "secondary",
            "type": {
              "coding": [
                {
                  "code": "PLAC"
                }
              ]
            },
            "value": "NCTA12313212"
          }
        ],
        "title": "Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimer’s Disease",
        "protocol": [
          {
            "reference": "PlanDefinition/LZZT-Study-Definition"
          }
        ],
        "status": "completed",
        "primaryPurposeType": {
          "coding": [
            {
              "code": "treatment"
            }
          ]
        },
        "phase": {
          "coding": [
            {
              "code": "phase-3"
            }
          ]
        },
        "category": [
          {
            "coding": [
              {
                "system": "http://ncimeta.nci.nih.gov",
                "code": "C98388",
                "display": "Interventional Study"
              }
            ]
          },
          {
            "coding": [
              {
                "system": "http://ncimeta.nci.nih.gov",
                "code": "C15417",
                "display": "Randomized Clinical Trial"
              }
            ]
          },
          {
            "coding": [
              {
                "system": "http://ncimeta.nci.nih.gov",
                "code": "C15228",
                "display": "Double Blind Study"
              }
            ]
          },
          {
            "coding": [
              {
                "system": "http://ncimeta.nci.nih.gov",
                "code": "C49648",
                "display": "Placebo Control"
              }
            ]
          },
          {
            "coding": [
              {
                "system": "http://ncimeta.nci.nih.gov",
                "code": "C82639",
                "display": "Parallel Study"
              }
            ]
          }
        ],
        "focus": [
          {
            "coding": [
              {
                "system": "http://ncimeta.nci.nih.gov",
                "code": "C152926",
                "display": "Xanomeline"
              }
            ]
          },
          {
            "coding": [
              {
                "system": "http://ncimeta.nci.nih.gov",
                "code": "C149996",
                "display": "Transdermal Patch Dosage Form"
              }
            ]
          }
        ],
        "condition": [
          {
            "coding": [
              {
                "system": "http://snomed.info/sct",
                "code": "26929004",
                "display": "Alzheimer's Disease (Disorder)"
              }
            ]
          },
          {
            "coding": [
              {
                "system": "http://snomed.info/sct",
                "code": "G30",
                "display": "Alzheimer's disease"
              }
            ]
          },
          {
            "coding": [
              {
                "system": "http://snomed.info/sct",
                "code": "10001896",
                "display": "Alzheimer's disease"
              }
            ]
          }
        ],
        "contact": [
          {
            "name": "Bob James, Ph.D.",
            "telecom": [
              {
                "system": "phone",
                "value": "555-555-5555",
                "use": "work"
              }
            ]
          }
        ],
        "relatedArtifact": [
          {
            "type": "documentation",
            "label": "Protocol H2Q-MC-LZZT(c)",
            "url": "https://clinicaltrials.gov/show/NCTA12313212/Lzzt_protocol_redacted.pdf"
          }
        ],
        "keyword": [
          {
            "coding": [
              {
                "system": "https://id.nlm.nih.gov/mesh",
                "code": "D018721"
              }
            ],
            "text": "Selective M1 muscarinic agonists"
          }
        ],
        "description": "# Xanomeline (LY246708)\n# Protocol H2Q-MC-LZZT(c) \nSafety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimer’s Disease",
        "sponsor": {
          "reference": "Organization/EliLillyAndCompany"
        },
        "principalInvestigator": {
          "reference": "Practitioner/SamGetWell"
        },
        "arm": [
          {
            "name": "Placebo",
            "type": {
              "coding": [
                {
                  "system": "http://ncimeta.nci.nih.gov",
                  "code": "C49648"
                }
              ]
            },
            "description": "Placebo arm"
          },
          {
            "name": "Low-dose xanomeline arm",
            "type": {
              "coding": [
                {
                  "system": "http://ncimeta.nci.nih.gov",
                  "code": "C174266"
                }
              ]
            },
            "description": "Low-dose xanomeline arm (50 cm2 TTS Formulation E, 54 mg xanomeline)"
          },
          {
            "name": "High-dose xanomeline arm",
            "type": {
              "coding": [
                {
                  "system": "http://ncimeta.nci.nih.gov",
                  "code": "C174266"
                }
              ]
            },
            "description": "High-dose xanomeline arm (75 cm2 TTS Formulation E, 81 mg xanomeline)"
          }
        ],
        "objective": [
          {
            "name": "To determine if there is a statistically significant relationship (overall Type 1 error rate, α=.05) between the change in both ADAS-Cog and CIBIC+ scores, and drug dose (0, 50 cm2 [54 mg], and 75 cm2 [81 mg]).",
            "type": {
              "coding": [
                {
                  "code": "primary"
                }
              ]
            }
          },
          {
            "name": "To document the safety profile of the xanomeline TTS.",
            "type": {
              "coding": [
                {
                  "code": "primary"
                }
              ]
            }
          },
          {
            "name": "To assess the dose-dependent improvement in behavior. Improved scores on the Revised Neuropsychiatric Inventory (NPI-X) will indicate improvement in these areas.",
            "type": {
              "coding": [
                {
                  "code": "secondary"
                }
              ]
            }
          },
          {
            "name": "To assess the dose-dependent improvements in activities of daily living. Improved scores on the Disability Assessment for Dementia (DAD) will indicate improvement in these areas.",
            "type": {
              "coding": [
                {
                  "code": "secondary"
                }
              ]
            }
          },
          {
            "name": "To assess the dose-dependent improvements in an extended assessment of cognition that integrates attention/concentration tasks. The Alzheimer’s Disease Assessment Scale-14 item Cognitive Subscale, hereafter referred to as ADAS-Cog (14), will be used for this assessment.",
            "type": {
              "coding": [
                {
                  "code": "secondary"
                }
              ]
            }
          },
          {
            "name": "To assess the treatment response as a function of Apo E genotype.",
            "type": {
              "coding": [
                {
                  "code": "secondary"
                }
              ]
            }
          }
        ]
      }
    },
    {
      "resource": {
        "resourceType": "PlanDefinition",
        "id": "H2Q-MC-LZZT-ProtocolDesign",
        "meta": {
          "profile": [
            "http://example.org/br-and-r/soa/StructureDefinition/SOA-PlanDefinition"
          ]
        },
        "text": {
          "status": "generated",
          "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p><b>Generated Narrative</b></p><p><b>version</b>: LZZT_1</p><p><b>status</b>: active</p><blockquote><p><b>action</b></p><p><b>title</b>: Visit-1</p><p><b>description</b>: Planned Visit [Visit-1]</p><p><b>definition</b>: <code>PlanDefinition/H2Q-MC-LZZT-Study-Visit-1</code></p></blockquote><blockquote><p><b>action</b></p><p><b>title</b>: Visit-2</p><p><b>description</b>: Planned Visit [Visit-2]</p><p><b>definition</b>: <code>PlanDefinition/H2Q-MC-LZZT-Study-Visit-2</code></p></blockquote><blockquote><p><b>action</b></p><p><b>title</b>: Visit-3</p><p><b>description</b>: Planned Visit [Visit-3]</p><p><b>definition</b>: <code>PlanDefinition/H2Q-MC-LZZT-Study-Visit-3</code></p></blockquote><blockquote><p><b>action</b></p><p><b>title</b>: Visit-4</p><p><b>description</b>: Planned Visit [Visit-4]</p><p><b>definition</b>: <code>PlanDefinition/H2Q-MC-LZZT-Study-Visit-4</code></p></blockquote><blockquote><p><b>action</b></p><p><b>title</b>: Visit-5</p><p><b>description</b>: Planned Visit [Visit-5]</p><p><b>definition</b>: <code>PlanDefinition/H2Q-MC-LZZT-Study-Visit-5</code></p></blockquote><blockquote><p><b>action</b></p><p><b>title</b>: Visit-6</p><p><b>description</b>: Planned Visit [Visit-6]</p><p><b>definition</b>: <code>PlanDefinition/H2Q-MC-LZZT-Study-Visit-6</code></p></blockquote><blockquote><p><b>action</b></p><p><b>title</b>: Visit-7</p><p><b>description</b>: Planned Visit [Visit-7]</p><p><b>definition</b>: <code>PlanDefinition/H2Q-MC-LZZT-Study-Visit-7</code></p></blockquote><blockquote><p><b>action</b></p><p><b>title</b>: Visit-8</p><p><b>description</b>: Planned Visit [Visit-8]</p><p><b>definition</b>: <code>PlanDefinition/H2Q-MC-LZZT-Study-Visit-8</code></p></blockquote><blockquote><p><b>action</b></p><p><b>title</b>: Visit-9</p><p><b>description</b>: Planned Visit [Visit-9]</p><p><b>definition</b>: <code>PlanDefinition/H2Q-MC-LZZT-Study-Visit-9</code></p></blockquote><blockquote><p><b>action</b></p><p><b>title</b>: Visit-10</p><p><b>description</b>: Planned Visit [Visit-10]</p><p><b>definition</b>: <code>PlanDefinition/H2Q-MC-LZZT-Study-Visit-10</code></p></blockquote><blockquote><p><b>action</b></p><p><b>title</b>: Visit-11</p><p><b>description</b>: Planned Visit [Visit-11]</p><p><b>definition</b>: <code>PlanDefinition/H2Q-MC-LZZT-Study-Visit-11</code></p></blockquote><blockquote><p><b>action</b></p><p><b>title</b>: Visit-12</p><p><b>description</b>: Planned Visit [Visit-12]</p><p><b>definition</b>: <code>PlanDefinition/H2Q-MC-LZZT-Study-Visit-12</code></p></blockquote><blockquote><p><b>action</b></p><p><b>title</b>: Visit-13</p><p><b>description</b>: Planned Visit [Visit-13]</p><p><b>definition</b>: <code>PlanDefinition/H2Q-MC-LZZT-Study-Visit-13</code></p></blockquote><blockquote><p><b>action</b></p><p><b>title</b>: ET-14</p><p><b>description</b>: Planned Visit [ET-14]</p><p><b>definition</b>: <code>PlanDefinition/H2Q-MC-LZZT-Study-ET-14</code></p></blockquote><blockquote><p><b>action</b></p><p><b>title</b>: RT-15</p><p><b>description</b>: Planned Visit [RT-15]</p><p><b>definition</b>: <code>PlanDefinition/H2Q-MC-LZZT-Study-RT-15</code></p></blockquote></div>"
        },
        "version": "LZZT_1",
        "status": "active",
        "action": [
          {
            "title": "Visit-1",
            "description": "Planned Visit [Visit-1]",
            "definitionUri": "PlanDefinition/H2Q-MC-LZZT-Study-Visit-1"
          },
          {
            "title": "Visit-2",
            "description": "Planned Visit [Visit-2]",
            "definitionUri": "PlanDefinition/H2Q-MC-LZZT-Study-Visit-2"
          },
          {
            "title": "Visit-3",
            "description": "Planned Visit [Visit-3]",
            "definitionUri": "PlanDefinition/H2Q-MC-LZZT-Study-Visit-3"
          },
          {
            "title": "Visit-4",
            "description": "Planned Visit [Visit-4]",
            "definitionUri": "PlanDefinition/H2Q-MC-LZZT-Study-Visit-4"
          },
          {
            "title": "Visit-5",
            "description": "Planned Visit [Visit-5]",
            "definitionUri": "PlanDefinition/H2Q-MC-LZZT-Study-Visit-5"
          },
          {
            "title": "Visit-6",
            "description": "Planned Visit [Visit-6]",
            "definitionUri": "PlanDefinition/H2Q-MC-LZZT-Study-Visit-6"
          },
          {
            "title": "Visit-7",
            "description": "Planned Visit [Visit-7]",
            "definitionUri": "PlanDefinition/H2Q-MC-LZZT-Study-Visit-7"
          },
          {
            "title": "Visit-8",
            "description": "Planned Visit [Visit-8]",
            "definitionUri": "PlanDefinition/H2Q-MC-LZZT-Study-Visit-8"
          },
          {
            "title": "Visit-9",
            "description": "Planned Visit [Visit-9]",
            "definitionUri": "PlanDefinition/H2Q-MC-LZZT-Study-Visit-9"
          },
          {
            "title": "Visit-10",
            "description": "Planned Visit [Visit-10]",
            "definitionUri": "PlanDefinition/H2Q-MC-LZZT-Study-Visit-10"
          },
          {
            "title": "Visit-11",
            "description": "Planned Visit [Visit-11]",
            "definitionUri": "PlanDefinition/H2Q-MC-LZZT-Study-Visit-11"
          },
          {
            "title": "Visit-12",
            "description": "Planned Visit [Visit-12]",
            "definitionUri": "PlanDefinition/H2Q-MC-LZZT-Study-Visit-12"
          },
          {
            "title": "Visit-13",
            "description": "Planned Visit [Visit-13]",
            "definitionUri": "PlanDefinition/H2Q-MC-LZZT-Study-Visit-13"
          },
          {
            "title": "ET-14",
            "description": "Planned Visit [ET-14]",
            "definitionUri": "PlanDefinition/H2Q-MC-LZZT-Study-ET-14"
          },
          {
            "title": "RT-15",
            "description": "Planned Visit [RT-15]",
            "definitionUri": "PlanDefinition/H2Q-MC-LZZT-Study-RT-15"
          }
        ]
      }
    }
  ]
}